<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20406" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Desmoid Tumor</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Master</surname>
            <given-names>Samip R.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mangla</surname>
            <given-names>Ankit</given-names>
          </name>
          <aff>Case Western Reserve University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shah</surname>
            <given-names>Chintan</given-names>
          </name>
          <aff>University of Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samip Master declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ankit Mangla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chintan Shah declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20406.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Desmoid tumor, a rare malignancy of mesenchymal origin, affects&#x000a0;a small proportion of the population with an incidence of 2&#x000a0;to 4 patients per million. Also known&#x000a0;as "aggressive fibromatosis" or "desmoid-type fibromatosis," these tumors&#x000a0;primarily impact the younger age group. Despite the absence of metastasis,&#x000a0;desmoid tumors exhibit local invasion,&#x000a0;leading to&#x000a0;severe morbidity.&#x000a0;The&#x000a0;association&#x000a0;with the <italic toggle="yes">APC</italic> gene mutation can&#x000a0;result in multifocal&#x000a0;DTs, occasionally leading to&#x000a0;mortality.</p>
        <p>The management of desmoid tumors poses a significant challenge due to the lack of a standard treatment approach. Although watchful observation is recommended for asymptomatic desmoid tumors&#x000a0;(20% can regress spontaneously), surgical resection has fallen out of favor due to high rates of recurrence. Systemic treatment options have increased with the recent approval of gamma-secretase inhibitor nirogacestat.&#x000a0;This activity describes&#x000a0;the epidemiology, genetics, clinical presentation, and management of desmoid tumors,&#x000a0;providing healthcare professionals with the knowledge and tools necessary to improve patient care for this rare yet complex tumor.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the signs and symptoms of&#x000a0;desmoid tumors and interpret the radiologic and pathologic findings.&#x000a0;</p></list-item><list-item><p>Screen for associated genetic mutations and identify hereditary syndromes.&#x000a0;</p></list-item><list-item><p>Select appropriate&#x000a0;systemic treatment for patients with desmoid tumors.</p></list-item><list-item><p>Collaborate with all interprofessional team members, including specialists such as surgical oncologists, orthopedic oncologists, sarcoma pathologists, radiologists, and pharmacists, to provide efficient, comprehensive, and coordinated care to patients diagnosed with desmoid tumors.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20406&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20406">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20406.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Desmoid tumors are mesenchymal neoplasms that are considered locally invasive but nonmetastasizing.<xref ref-type="bibr" rid="article-20406.r1">[1]</xref><xref ref-type="bibr" rid="article-20406.r2">[2]</xref><xref ref-type="bibr" rid="article-20406.r3">[3]</xref>&#x000a0;They are also known as aggressive fibromatosis, deep fibromatosis, and musculoaponeurotic fibromatosis. Even though they do not metastasize, they are locally invasive and cause significant morbidity and mortality. There is no standard approach to treating desmoid tumors; managing them&#x000a0;is challenging and requires discussion at a multidisciplinary tumor board.&#x000a0;</p>
        <p>Despite surgical resection,&#x000a0;desmoid tumors have a high rate of local recurrence;&#x000a0;accordingly, they have been labeled as intermediate locally aggressive tumors by the World Health Organization (WHO).<xref ref-type="bibr" rid="article-20406.r4">[4]</xref> According to WHO,&#x000a0;desmoid tumor is a "clonal fibroblastic proliferation that arises in&#x000a0;the deep soft tissues and is characterized by infiltrative growth and a tendency toward local recurrence but an inability to metastasize," even though it may be multifocal in the same limb or body part. Systemic&#x000a0;treatment is used in patients where surgery and&#x000a0;radiation therapy&#x000a0;are either not feasible or will not achieve a cure. Recently, several new drugs have been licensed by the United States Food and Drug Administration (FDA) to treat patients with DT.</p>
      </sec>
      <sec id="article-20406.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of&#x000a0;desmoid tumor is unknown.&#x000a0;Most desmoid tumors occur sporadically, and 85% have a mutation in the <italic toggle="yes">CTNNB1</italic> encoding &#x000df;-catenin pathway. The&#x000a0;3 distinct mutations identified are 41A, 45F, and 45. Mutation 45F is associated with a high risk of recurrence.<xref ref-type="bibr" rid="article-20406.r4">[4]</xref><xref ref-type="bibr" rid="article-20406.r5">[5]</xref><xref ref-type="bibr" rid="article-20406.r6">[6]</xref> The 5-year recurrence-free survival rate has been reported to be 23% for patients with a 45F mutation, 57% for patients with a 41A mutation, and 65% for those with no mutations.</p>
        <p>Desmoid tumor is seen at increased frequency in&#x000a0;familial adenomatous polyposis (FAP), mostly abdominal FAP&#x000a0;caused by a mutation in the <italic toggle="yes">APC</italic> gene. Desmoid tumor arising in FAP has a predilection for the prior surgical site, and previous surgery is a risk factor. In patients who are treated with prophylactic colectomy,&#x000a0;desmoid tumor is the more important cause of morbidity and mortality than colon cancer. Desmoid tumor occurs with increased frequency in females during or after pregnancy, and anecdotal evidence suggests abdominal wall trauma and high estrogen states are the possible reasons. Pregnancy-associated&#x000a0;desmoid tumor has overall better outcomes.</p>
      </sec>
      <sec id="article-20406.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Desmoid tumor&#x000a0;is a rare tumor, with a reported incidence of 2&#x000a0;to 4 patients per million, and accounts for 0.03% of all neoplasms.<xref ref-type="bibr" rid="article-20406.r7">[7]</xref>&#x000a0;The peak age of occurrence is 30&#x000a0;to 40 years. It occurs more commonly in women compared&#x000a0;with men and most often between the ages of 15&#x000a0;and 60 years.<xref ref-type="bibr" rid="article-20406.r8">[8]</xref><xref ref-type="bibr" rid="article-20406.r9">[9]</xref> DT may occur at abdominal, intra-abdominal,&#x000a0;and extra-abdominal locations.<xref ref-type="bibr" rid="article-20406.r9">[9]</xref> Approximately 5% to 10% arise in the context of FAP.<xref ref-type="bibr" rid="article-20406.r10">[10]</xref></p>
      </sec>
      <sec id="article-20406.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of&#x000a0;desmoid tumor lies in the dysregulation of the Wnt pathway. Mutation in the <italic toggle="yes">&#x000df;-catenin</italic> gene or germline mutation in the adenomatous polyposis coli (<italic toggle="yes">APC</italic>)&#x000a0;gene leads to the accumulation of the &#x003b2;-catenin protein; in turn, &#x003b2;-catenin is translocated to the nucleus and activates the expression of the <italic toggle="yes">Wnt</italic> gene. Subsequently, several proteins, including cyclo-oxygenase 1 (COX-2) and vascular endothelial growth factor, are produced, leading to tumor growth. These proteins are also the target of some medicines used in treating desmoid tumor.<xref ref-type="bibr" rid="article-20406.r11">[11]</xref></p>
      </sec>
      <sec id="article-20406.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The diagnosis of&#x000a0;desmoid tumor&#x000a0;must be reviewed by an expert soft-tissue pathologist. Histologically,&#x000a0;desmoid tumor&#x000a0;is characterized by the proliferation of uniform spindle cells resembling myofibroblasts in the background of abundant collagenous stroma and the vascular network.<xref ref-type="bibr" rid="article-20406.r12">[12]</xref>&#x000a0;Other features like hyperchromasia and cellular atypia are not usually present. The tumor cells are similar to the myofibroblasts, as seen during the proliferative stage of wound healing, and may&#x000a0;have nuclei containing euchromatin or heterochromatin.<xref ref-type="bibr" rid="article-20406.r13">[13]</xref>&#x000a0;Large amounts of the myxoid stroma may be seen in some tumors, especially those that develop in the mesentery. On microscopy, the tumor may appear like a low-grade fibrosarcoma, but the cells lack the nuclear atypia and typical cytoplasmic features of malignancy.</p>
        <p>On immunohistochemistry,&#x000a0;desmoid tumor stains positive for nuclear &#x000df;-catenin, vimentin, COX-2, tyrosine kinase <italic toggle="yes">PDGFRB</italic>, androgen receptor, and estrogen receptor beta.&#x000a0;Desmoid tumor stains negative for desmin, S-100, h-caldesmon, CD34, and c-KIT.<xref ref-type="bibr" rid="article-20406.r13">[13]</xref>&#x000a0;Nuclear &#x000df;-catenin positivity supports the diagnosis of desmoid tunmor.&#x000a0;However, a negative stain does not exclude desmoid tumor.</p>
        <p>Next-generation sequencing must be done to evaluate for <italic toggle="yes">CTNNB1</italic> mutations.&#x000a0;The <italic toggle="yes">CTNNB1</italic> and <italic toggle="yes">APC</italic> mutations are mutually exclusive. Hence, the detection of one can virtually exclude the other. In patients that are <italic toggle="yes">CTNNB1</italic> wild-type, especially for intra-abdominal desmoid tumor, extensive clinical workup should be pursued to rule out FAP syndrome (also known as Gardner's syndrome).&#x000a0;</p>
      </sec>
      <sec id="article-20406.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Desmoid tumor&#x000a0;has a varied pattern of clinical presentation, characterized by a slow-growing tumor that can stabilize and even undergo spontaneous remission.&#x000a0;Desmoid tumor commonly occurs in the rectus abdomens muscle, head and neck region, pelvis, and extremities.&#x000a0;Desmoid tumor is also known to occur in association with pregnancy and with the use of oral contraceptive pills, and it is known to regress with menopause, indicating a potential influence of the female sex hormonal environment. Breast desmoid tumors can be associated with surgery or implants. One in&#x000a0;4 cases has a history of trauma or surgery at the site of the desmoid tumor.&#x000a0;Desmoid tumor also tends to recur in the same area, causing local destruction; however, it cannot metastasize.</p>
        <p>In patients with multiple desmoid tumors, it is considered to be a "multifocal" disease rather than a metastatic disease.&#x000a0;Patients with FAP are at a much higher risk of developing&#x000a0;desmoid tumors (up to 25% higher than the general population). In patients with desmoid tumors, FAP can be diagnosed in up to 5% of patients. The peak incidence is in the late second decade of life, although it can occur at any age.&#x000a0;The physical exam is usually benign unless the tumor causes pressure symptoms. They can undoubtedly mimic cancer of the respective organ (for example, a desmoid tumor occurring in the breast can mimic breast cancer); hence, a biopsy is mandatory to accurately diagnose a desmoid tumor.</p>
      </sec>
      <sec id="article-20406.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Imaging Studies</bold>
</p>
        <p>Imaging studies<bold>&#x000a0;</bold>like CT scans and MRIs can be done during diagnosis and follow-up. Imaging can determine the extent of the tumor, which organs are infiltrated, and a surgical resection&#x000a0;plan.<xref ref-type="bibr" rid="article-20406.r14">[14]</xref><xref ref-type="bibr" rid="article-20406.r15">[15]</xref><xref ref-type="bibr" rid="article-20406.r16">[16]</xref>&#x000a0;An MRI seems more useful than a CT scan in helping to establish the extent of the tumor and its relationship to nearby organs.&#x000a0;On T1-weighted images, desmoids are hypo- or isointense to muscle,&#x000a0;whereas T2-weighted images are hyperintense. With gadolinium contrast,&#x000a0;DT shows moderate enhancement with hypo-intense bands because of collagen bundles.</p>
        <p>
<bold>Histological Evaluation</bold>
</p>
        <p>Histological evaluation is needed to confirm the diagnosis. An incisional biopsy is preferred, but a careful biopsy may be sufficient. Histological features are as previously described in histopathology.</p>
        <p>
<bold>Immunostaining</bold>
</p>
        <p>Immunostaining with vimentin, alpha-smooth muscle actin, muscle actin, and desmin helps distinguish the tumors.</p>
        <p>
<bold>Next-Generation Sequencing</bold>
</p>
        <p>Most guidelines recommend the use of next-generation&#x000a0;sequencing to identify druggable targets.&#x000a0;</p>
        <p>
<bold>Colonoscopy and Genetic Assessment</bold>
</p>
        <p>Desmoid tumor is more common in adolescents and young adults. Its association with FAP syndrome needs a thorough evaluation with colonoscopy and genetic assessment in patients who first present with desmoid tumors.&#x000a0;</p>
      </sec>
      <sec id="article-20406.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is no standard approach to&#x000a0;managing desmoid tumor. Most experts recommend watchful observation in asymptomatic patients. In symptomatic patients, several treatment approaches have been proposed. Surgical resection has taken a backseat in the management of&#x000a0;desmoid tumor&#x000a0;due to high recurrence rates and morbid resections. Medical management has advanced significantly in the last&#x000a0;2 decades.<xref ref-type="bibr" rid="article-20406.r10">[10]</xref>&#x000a0;</p>
        <p>
<bold>Surgical Treatment</bold>
</p>
        <p>Surgery aims to preserve the limb function and critical structures. Unlike other soft-tissue sarcomas, where surgical resection aims to achieve microscopic negative margins (R0 resection), an R0 resection is only deemed "desirable" but not a necessity in the surgery of a desmoid tumor. The significance of a positive margin (R1 or R2 resection) is highly debated. Positive margins after surgery have been reported as an independent prognostic factor in determining the risk of recurrence. However,&#x000a0;a morbid surgery in an attempt to achieve an R0 resection is not indicated. In combination with&#x000a0;radiation and medical therapies, the treatment of&#x000a0;desmoid tumor&#x000a0;has become more conservative.</p>
        <p>
<bold>Radiation Therapy</bold>
</p>
        <p>Radiation therapy&#x000a0;is primarily used in the adjuvant setting when surgery leaves behind a positive margin, or surgical resection is impossible. A dose of more than 56 Gy is associated with many complications and hence avoided. Nonrandomized and retrospective data have shown a lower local recurrence rate with the addition of adjuvant RT in patients with a positive margin. The role of neoadjuvant radiation therapy&#x000a0;has&#x000a0;not been established and is currently not recommended.</p>
        <p>
<bold>Systemic Therapy</bold>
</p>
        <p>Systemic therapy is usually reserved for patients who experience rapid growth of&#x000a0;a desmoid tumor,&#x000a0;or for those patients in whom the tumor is threatening a critical structure&#x000a0;(otherwise&#x000a0;the surgery would be highly mutilating).&#x000a0;</p>
        <p>
<bold>Chemotherapy</bold>
</p>
        <p>Desmoid tumor&#x000a0;is not a chemosensitive tumor; however, few regimens may benefit patients.</p>
        <p>
<bold>Doxorubicin-based Regimens</bold>
</p>
        <p>Doxorubicin-based regimens have had the best success rates. The combination of doxorubicin and dacarbazine has been shown to induce a partial response. Typically, the response in the tumor is slow and may occur for months after chemotherapy has been stopped. In patients with&#x000a0;desmoid tumor associated with FAP, the addition of&#x000a0;nonsteroidal antiinflammatory drugs&#x000a0;(like meloxicam) is beneficial. Liposomal doxorubicin is also an effective drug, inducing long-lasting responses in many patients.&#x000a0;</p>
        <p>
<bold>Vinca Alkaloids With Methotrexate&#x000a0;</bold>
</p>
        <p>In the pediatric population, the combination of vinblastine and&#x000a0;methotrexate has been found beneficial; however, this combination is very toxic for adults. Hence, in adults, vinblastine is substituted for vinorelbine and is given along with methotrexate.</p>
        <p>
<bold>Targeted Therapy</bold>
</p>
        <p>
<bold>Imatinib</bold>
</p>
        <p>Imatinib (800 mg daily) has been successfully used in patients with desmoid tumor. However, no definite mechanism or pathway of action is known. Even those patients without any mutation in the <italic toggle="yes">KIT</italic>, <italic toggle="yes">PDGRA</italic>, or <italic toggle="yes">PDGFRB</italic> regions showed a response.&#x000a0;</p>
        <p>
<bold>Sorafenib&#x000a0;</bold>
</p>
        <p>Sorafenib (400 mg daily) was explored in a phase III randomized, double-blinded trial against a placebo and was found to significantly prolong progression-free survival (hazard ratio for progression or death, 0.13; 95% CI, 0.05-0.31; <italic toggle="yes">P</italic>&#x0003c;0.001). The objective response rate was 33% in the sorafenib group compared&#x000a0;with 20% in the placebo group. Rash, hypertension, diarrhea, and fatigue were the most common grade 3 or higher adverse events.<xref ref-type="bibr" rid="article-20406.r17">[17]</xref>&#x000a0;</p>
        <p>
<bold>Nirogacestat&#x000a0;</bold>
</p>
        <p>Nirogacestat (150 mg twice a day) is the first gamma-secretase inhibitor granted full USFDA approval for patients with DT whose tumors&#x000a0;are progressing. Nirogacestat was studied in a phase III, double-blinded randomized control trial against a placebo. The drug was approved based on the significant benefit of the progression-free survival (hazard ratio for disease progression or death, 0.29; 95% confidence interval, 0.15-0.55; <italic toggle="yes">P</italic>&#x0003c;0.001), response rate (41% versus 8%, <italic toggle="yes">P</italic>&#x0003c;0.001) and a significant reduction in pain, symptoms burden, physical and functional role. Diarrhea, nausea, fatigue, and rash were amongst the significant grade 3 or higher adverse events.<xref ref-type="bibr" rid="article-20406.r18">[18]</xref>&#x000a0;</p>
        <p>
<bold>Hormonal Therapy</bold>
</p>
        <p>Hormonal therapy is usually prescribed in combination with nonsteroidal anti-inflammatory drugs (COX-2 inhibitors). However, this approach to the treatment of&#x000a0;desmoid tumor has fallen out of favor and is no longer recommended.&#x000a0;</p>
      </sec>
      <sec id="article-20406.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses for desmoid tumor include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Breast cancer</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dermatological manifestations of Gardner&#x02019;s syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Familiar polyposis of the colon</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fibrosarcoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal stromal tumor&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Inflammatory myofibroblastic tumor&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Retroperitoneal fibrosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sclerosing mesenteritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Solitary fibrous tumor&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20406.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Desmoid tumors&#x000a0;do not cause mortality except when associated with FAP syndrome; however, they are associated with high morbidity due to local destruction. Additionally, up to 20% of patients can experience spontaneous remission of the tumors. Hence, it is essential to consider each patient on a case-by-case basis. Surgical resection is now avoided due to morbid resections, which are often futile due to high recurrence rates.&#x000a0;</p>
      </sec>
      <sec id="article-20406.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Most complications from&#x000a0;desmoid tumor&#x000a0;arise due to local compression of the neurovascular structures or invasion of the neighboring viscera or bones. Symptoms occur depending on which part of the body is involved. Slow-growing&#x000a0;desmoid tumors (&#x0003c;10% growth in 3 months by imaging) can be observed, especially if asymptomatic. Patients presenting with significant symptoms of pain, deformity, or neurovascular compromise may need to be initiated on treatment sooner rather than later.&#x000a0;</p>
      </sec>
      <sec id="article-20406.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients and healthcare professionals must appreciate the rarity of desmoid tumors. The diagnosis and treatment pose a particular challenge to the clinician due to the lack of a standard approach. Although the word "tumor" creates a general sense of alarm among patients, healthcare professionals must emphasize the peculiar nature of&#x000a0;desmoid tumor and the low mortality associated with this type of tumor. The need for genetic counseling and screening colonoscopy, especially in adolescents and young adults, must be discussed.&#x000a0;Finally, all patients should receive encouragement to participate in clinical trials.</p>
      </sec>
      <sec id="article-20406.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Pearls for healthcare professionals:</p>
        <list list-type="bullet">
          <list-item>
            <p>Desmoid tumors do not metastasize&#x000a0;(although they can be multifocal).</p>
          </list-item>
          <list-item>
            <p>Eighty-five percent of desmoid tumor cases are sporadic.</p>
          </list-item>
          <list-item>
            <p>DT is associated with low mortality but high morbidity.</p>
          </list-item>
          <list-item>
            <p>Observation is recommended in all patients with slow-growing desmoid tumors (&#x0003c;10% growth in 3 months on imaging). Up to 20% of patients will experience spontaneous remission.</p>
          </list-item>
          <list-item>
            <p>Surgical resection is&#x000a0;no longer the preferred treatment due to high recurrence rates despite a morbid resection.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Systemic treatment with chemotherapy is not preferred due to the demonstrated efficacy of targeted therapy.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Sorafenib is a multikinase tyrosine kinase inhibitor with demonstrated&#x000a0;progression-free survival&#x000a0;benefit in patients with&#x000a0;desmoid tumor&#x000a0;requiring systemic therapy (typical dose: 400 mg daily).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nirogacestat is the first gamma-secretase inhibitor to receive approval from the FDA for patients with&#x000a0;desmoid tumor requiring systemic therapy (typical dose: 150 mg twice a day).&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20406.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Desmoid tumors are usually detected as a solitary mass in a patient presenting to the emergency room with symptoms of pain or in the office of a primary care physician. Because the diagnosis and treatment are complex, consulting with an oncologist, pathologist, and radiologist is important. The treatment of&#x000a0;desmoid tumor can be divided&#x000a0;broadly&#x000a0;into asymptomatic resectable, symptomatic resectable, unresectable, and recurrent desmoids. A multidisciplinary discussion is essential to guide the treatment and prevent morbidity. Surgical resections are avoided due to high morbidity and high recurrence rates. Pharmacists and nurses play a critical role in managing the toxicities of the various systemic treatments. DT is associated with low mortality and high morbidity. The genetics team needs to be involved in the care of young patients.<xref ref-type="bibr" rid="article-20406.r19">[19]</xref><xref ref-type="bibr" rid="article-20406.r20">[20]</xref><xref ref-type="bibr" rid="article-20406.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20406.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20406&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20406">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/desmoid-tumor/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20406">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20406/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20406">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20406.s17">
        <title>References</title>
        <ref id="article-20406.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <collab>PDQ Pediatric Treatment Editorial Board</collab>
            <chapter-title>Childhood Soft Tissue Sarcoma Treatment (PDQ&#x000ae;): Health Professional Version</chapter-title>
            <source>PDQ Cancer Information Summaries [Internet]</source>
            <publisher-name>National Cancer Institute (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>8</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">26389361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>En bloc resection for intra-abdominal/retroperitoneal desmoid-type fibromatosis with adjacent organ involvement: A case series and literature review.</article-title>
            <source>Biosci Trends</source>
            <year>2018</year>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>620</fpage>
            <page-range>620-626</page-range>
            <pub-id pub-id-type="pmid">30674762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cassidy</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Lefkowitz</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>LX</given-names>
              </name>
              <name>
                <surname>Kirane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sbaity</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hameed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coit</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Crago</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation: A Retrospective Cohort Study.</article-title>
            <source>Ann Surg</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>271</volume>
            <issue>4</issue>
            <fpage>748</fpage>
            <page-range>748-755</page-range>
            <pub-id pub-id-type="pmid">30418203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganeshan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nikolaidis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Assing</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vikram</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Current Update on Desmoid Fibromatosis.</article-title>
            <source>J Comput Assist Tomogr</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-38</page-range>
            <pub-id pub-id-type="pmid">30211798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Timbergen</surname>
                <given-names>MJM</given-names>
              </name>
              <name>
                <surname>van de Poll-Franse</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nhagen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>van der Graaf</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Sleijfer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verhoef</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Husson</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study.</article-title>
            <source>Qual Life Res</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>12</issue>
            <fpage>3097</fpage>
            <page-range>3097-3111</page-range>
            <pub-id pub-id-type="pmid">30014458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Couto Netto</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Menegozzo</surname>
                <given-names>CAM</given-names>
              </name>
              <name>
                <surname>Le&#x000e3;o-Filho</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Albertini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Akaishi</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Utiyama</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Sporadic Abdominal Wall Desmoid type Fibromatosis: treatment paradigm after thirty two years.</article-title>
            <source>BMC Surg</source>
            <year>2018</year>
            <month>Jun</month>
            <day>07</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <pub-id pub-id-type="pmid">29879959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nieuwenhuis</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Casparie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mathus-Vliegen</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Dekkers</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Vasen</surname>
                <given-names>HF</given-names>
              </name>
            </person-group>
            <article-title>A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses.</article-title>
            <source>Int J Cancer</source>
            <year>2011</year>
            <month>Jul</month>
            <day>01</day>
            <volume>129</volume>
            <issue>1</issue>
            <fpage>256</fpage>
            <page-range>256-61</page-range>
            <pub-id pub-id-type="pmid">20830713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Camargo</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Keohan</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>D'Adamo</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Antonescu</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor).</article-title>
            <source>Cancer</source>
            <year>2010</year>
            <month>May</month>
            <day>01</day>
            <volume>116</volume>
            <issue>9</issue>
            <fpage>2258</fpage>
            <page-range>2258-65</page-range>
            <pub-id pub-id-type="pmid">20187095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>MacNeill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gronchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Desmoid-Type Fibromatosis: Evolving Treatment Standards.</article-title>
            <source>Surg Oncol Clin N Am</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>803</fpage>
            <page-range>803-26</page-range>
            <pub-id pub-id-type="pmid">27591500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <collab>Desmoid Tumor Working Group</collab>
            <article-title>The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients.</article-title>
            <source>Eur J Cancer</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>127</volume>
            <fpage>96</fpage>
            <page-range>96-107</page-range>
            <pub-id pub-id-type="pmid">32004793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spolverato</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Capelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gounder</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of Desmoid Tumors.</article-title>
            <source>Surg Oncol Clin N Am</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>447</fpage>
            <page-range>447-458</page-range>
            <pub-id pub-id-type="pmid">35715144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muller</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Castagnaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yandel</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Alman</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Molecular genetic and immunohistochemical analysis of the tumor suppressor genes Rb and p53 in palmar and aggressive fibromatosis.</article-title>
            <source>Diagn Mol Pathol</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>194</fpage>
            <page-range>194-200</page-range>
            <pub-id pub-id-type="pmid">8866233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotiligam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Lev</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Desmoid tumor: a disease opportune for molecular insights.</article-title>
            <source>Histol Histopathol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-26</page-range>
            <pub-id pub-id-type="pmid">17952864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guttadauro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maternini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frassani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guanziroli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lo Bianco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gabrielli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Desmoid tumor of the abdominal wall A case report and literature review.</article-title>
            <source>Ann Ital Chir</source>
            <year>2017</year>
            <month>Nov</month>
            <day>20</day>
            <volume>6</volume>
            <pub-id pub-id-type="pmid">29424372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asadoorian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matcuk</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Tomasian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wassef</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Musculoskeletal Pitfalls on Fluorodeoxyglucose F 18 PET-Computed Tomography: Pictorial Review.</article-title>
            <source>PET Clin</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>587</fpage>
            <page-range>587-607</page-range>
            <pub-id pub-id-type="pmid">30219190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Attanoos</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Pugh</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>The Diagnosis of Pleural Tumors Other Than Mesothelioma.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>142</volume>
            <issue>8</issue>
            <fpage>902</fpage>
            <page-range>902-913</page-range>
            <pub-id pub-id-type="pmid">30040453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gounder</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mahoney</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Van Tine</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Ravi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Attia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deshpande</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Milhem</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Conry</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Movva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pishvaian</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Riedel</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Sabagh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tap</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Horvat</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Basch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Agaram</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Lefkowitz</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mazaheri</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Dueck</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Sorafenib for Advanced and Refractory Desmoid Tumors.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Dec</month>
            <day>20</day>
            <volume>379</volume>
            <issue>25</issue>
            <fpage>2417</fpage>
            <page-range>2417-2428</page-range>
            <pub-id pub-id-type="pmid">30575484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gounder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ratan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alcindor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;ffski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van der Graaf</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Wilky</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Riedel</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Moody</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Attia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D'Amato</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Federman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Merriam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van Tine</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Vincenzi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bui</surname>
                <given-names>NQ</given-names>
              </name>
              <name>
                <surname>Chugh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tinoco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Charlson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dileo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hartner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lapeire</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mazzeo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Palmerini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reichardt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cote</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Deshpande</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grignani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Loggers</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pressey</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Kummar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Nirogacestat, a &#x003b3;-Secretase Inhibitor for Desmoid Tumors.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Mar</month>
            <day>09</day>
            <volume>388</volume>
            <issue>10</issue>
            <fpage>898</fpage>
            <page-range>898-912</page-range>
            <pub-id pub-id-type="pmid">36884323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bishop</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Zarzour</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ratan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Feig</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Roland</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Guadagnolo</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Outcomes for Patients With Desmoid Fibromatosis Treated With Radiation Therapy: A 10-Year Update and Re-evaluation of the Role of Radiation Therapy for Younger Patients.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>103</volume>
            <issue>5</issue>
            <fpage>1167</fpage>
            <page-range>1167-1174</page-range>
            <pub-id pub-id-type="pmid">30552963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20406.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alghamdi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Henning</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kurien</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bouchard-Fortier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schiller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Puloski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Monument</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Itani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Surgical excision versus observation as initial management of desmoid tumors: A population based study.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>699</fpage>
            <page-range>699-703</page-range>
            <pub-id pub-id-type="pmid">30420189</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
